Risk | Very High |
---|---|
Min SIP Amount | Not Supported |
Expense Ratio | NaN% |
NAV | ₹13.73 (07 Apr 2021) |
---|---|
Fund Started | 12 Feb 2018 |
Fund Size | ₹410 Cr |
Name | Sector | Instrument | % Assets |
---|---|---|---|
Infosys Ltd. | Technology | Equity | 8.2% |
ICICI Bank Ltd. | Financial | Equity | 6.9% |
Bharti Airtel Ltd. | Communication | Equity | 6.8% |
Cipla Ltd. | Healthcare | Equity | 5.0% |
Axis Bank Ltd. | Financial | Equity | 4.8% |
Eicher Motors Ltd. | Automobile | Equity | 4.1% |
ITC Ltd. | FMCG | Equity | 3.9% |
Crompton Greaves Consumer Electricals Ltd. | Cons Durable | Equity | 3.8% |
Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 2.9% |
Ipca Laboratories Ltd. | Healthcare | Equity | 2.5% |
UTI Focussed Equity Fund Series VI (1150 Days) Direct Growth is a Equity Mutual Fund Scheme launched by UTI Mutual Fund. This scheme was made available to investors on 12 Feb 2018. Vetri Subramaniam, Sachin Trivedi is the Current Fund Manager of UTI Focussed Equity Fund Series VI (1150 Days) Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹410 Cr and the Latest NAV as of 07 Apr 2021 is ₹13.73.
The UTI Focussed Equity Fund Series VI (1150 Days) Direct Growth is rated Very High risk.
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of listed companies. The scheme will without any capitalization bias endeavour to invest in either growth stocks or value stocks or both. The Scheme will normally hold upto 30 stocks in the portfolio.